ArticleScientific reports2025
Combining clinical markers can predict mortality in NYHA IV heart failure.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Early assessment of heart failure during treatment can improve patient prognosis. Brain natriuretic peptide (BNP), uric acid (UA), pre-albumin (PA), red blood cell distribution width (RDW), and Cystatin C (Cys C) are related to the development of heart failure. This study determined whether these characteristics could serve as combined diagnostic indicators for the prognosis of New York Heart Association classification (NYHA) IV heart failure (IV-HF). Here, the general clinical and cardiac ultrasound data from 193 patients with NYHA IV-HF were collected and followed-up for six months, and their survival status was recorded. Among the patients, 119 (61.66%) survived, whereas 74 (38.34%) were reported dead at the six-month follow-up. Compared to the survival group, the death group had significantly higher age, disease duration, Cys C, UA, BNP, RDW, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, and left atrial dimension, and lower PA and left ventricular ejection fraction (LVEF). Cys C, UA, BNP, and RDW had significant negative linear correlations with LVEF, while PA had a significant positive linear correlation with LVEF. In addition, high Cys C, UA, BNP, and RDW, as well as low PA, are independent risk factors for mortality in patients with IV-HF. The combination of age, disease duration, RDW, and levels of Cys C, UA, BNP, and PA can serve as diagnostic indicators for mortality in patients with NYHA IV-HF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.